Heart Failure Reviews

, Volume 19, Issue 3, pp 295–304 | Cite as

Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases



While atrial fibrillation is common comorbidity in patients with cardiomyopathy and heart failure, diagnosis and management often focuses on tackling rate and rhythm control rather than elucidating pathogenic mechanisms related to underlying myocardial substrates. This review summarizes our current understanding of the natural history of cardiomyopathies presenting with atrial fibrillation, and the importance of managing underlying cardiomyopathic condition as diagnostic and treatment strategy for atrial fibrillation.


Atrial fibrillation Cardiomyopathy Genetic 


  1. 1.
    Wang TJ et al (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham heart study. Circulation 107:2920–2925PubMedCrossRefGoogle Scholar
  2. 2.
    Miyasaka Y et al (2006) Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J 27:936–941. doi:10.1093/eurheartj/ehi694 PubMedCrossRefGoogle Scholar
  3. 3.
    Kannel WB et al (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82(8A):2N–9NPubMedCrossRefGoogle Scholar
  4. 4.
    Tedesco MA et al (2001) Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study. Clin Cardiol 24:603–607PubMedCrossRefGoogle Scholar
  5. 5.
    Hammwohner M, Goette A (2011) Evidence for mechano-electric coupling from clinical trials on AF. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 395–401Google Scholar
  6. 6.
    Kalifa J et al (2003) Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 108:668–671PubMedCrossRefGoogle Scholar
  7. 7.
    Franz MR, Bode F (2011) Acute stretch effects on atrial electrophysiology. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 168–172Google Scholar
  8. 8.
    Camm J et al (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369–2429PubMedCrossRefGoogle Scholar
  9. 9.
    Kamkin A et al (2000) Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 48(3):409–420PubMedCrossRefGoogle Scholar
  10. 10.
    Spach MS et al (2001) Changes in anisotropic conduction caused by remodeling cell size and the cellular distribution of gap junctions and Na(+) channels. J Electrocardiol 34(Suppl):69–76PubMedCrossRefGoogle Scholar
  11. 11.
    Schotten U (2011) Mechano-electric coupling from in chronic AF. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 204–211Google Scholar
  12. 12.
    Dawson K, Wu C-T, Qi XY, Nattel S (2012) Congestive heart failure effects on atrial fibroblast phenotype: differences between freshly-isolated and cultured cells. PLoS ONE 7(12):e52032. doi:10.1371/journal.pone.0052032 PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Ichiki T et al (2013) Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol 304(2):R102–R109. doi:10.1152/ajpregu.00233.2012 PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Kottkamp H (2012) Atrial fibrillation substrate: the “unknown species”—from lone atrial fibrillation to fibrotic atrial cardiomyopathy. Heart Rhythm 9(4):481–482PubMedCrossRefGoogle Scholar
  15. 15.
    Mahnkopf C et al (2010) Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm 7:1475–1481PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Oakes RS et al (2009) Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119:1758–1767PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Teh AW et al (2012) Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm 9(4):473–480PubMedCrossRefGoogle Scholar
  18. 18.
    Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet 381(9862):242–255PubMedCrossRefGoogle Scholar
  19. 19.
    Darby AE, Dimarco JP (2012) Management of atrial fibrillation in patients with structural heart disease. Circulation 125(7):945–957PubMedCrossRefGoogle Scholar
  20. 20.
    Bunch TJ et al (2008) Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 19:1009–1014PubMedCrossRefGoogle Scholar
  21. 21.
    Kilicaslan F et al (2006) Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 3(3):275–280PubMedCrossRefGoogle Scholar
  22. 22.
    Di Donna P et al (2010) Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 12:347–355PubMedCrossRefGoogle Scholar
  23. 23.
    Seidman JE, Pyeritz RE, Seidman CE (2012) Inherited causes of cardiovascular disease. In: Bonow R, Mann D, Zipes D, Libby P (eds) Braunwald’s heart disease a textbook of cardiovascular medicine, 9th edn. Elsevier, Amsterdam, pp 70–79CrossRefGoogle Scholar
  24. 24.
    Maron BJ et al (2009) Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301(12):1253–1259PubMedCrossRefGoogle Scholar
  25. 25.
    Bounce D et al (2011) Natural history of Danon disease. Genet Med 13(6):563–568CrossRefGoogle Scholar
  26. 26.
    Cheng Z, Cui Q, Tian Z et al (2012) Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. Eur Heart J 33(5):649–656PubMedCrossRefGoogle Scholar
  27. 27.
    Gollob MH et al (2002) PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 17:229–234PubMedCrossRefGoogle Scholar
  28. 28.
    Clarke JT et al (2007) Narrative review: Fabry disease. Ann Intern Med 146(6):425–433PubMedCrossRefGoogle Scholar
  29. 29.
    Acharya D et al (2012) Arrhythmias in Fabry cardiomyopathy. Clin Cardiol 35(12):738–740PubMedCrossRefGoogle Scholar
  30. 30.
    Thavendiranathan P, Dahiya A, Phelan D, Desai MY, Tang WH (2013) Isolated left ventricular noncompaction controversies in diagnosis. Heart 99(10):681–689PubMedCrossRefGoogle Scholar
  31. 31.
    Connolly HM, Attenhofer JC (2013) Isolated left ventricular non-compaction. UpToDateGoogle Scholar
  32. 32.
    Ammash NA, Tajik JA (2013) Idiopathic restrictive cardiomyopathy. UpToDateGoogle Scholar
  33. 33.
    Falk R, Dubrey S (2010) Amyloid heart disease. In: Gertz MA, Rajkumar SV (eds) Amyloidosis: diagnosis and treatment. Humana Press, Clifton, pp 107–128CrossRefGoogle Scholar
  34. 34.
    Feng D et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420PubMedCrossRefGoogle Scholar
  35. 35.
    Feng D et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490–2497Google Scholar
  36. 36.
    Redfield MM et al (2000) Tachycardia related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for AV node ablation. Mayo Clin Proc 75:790–795PubMedCrossRefGoogle Scholar
  37. 37.
    Deshmukh PM et al (2004) Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 13:455–464PubMedGoogle Scholar
  38. 38.
    Moe GW et al (1993) Left ventricular myocardial blood flow, metabolism and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med 131:294–302Google Scholar
  39. 39.
    Spinale FG et al (1992) Myocardial Na, K-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 24:277–289PubMedCrossRefGoogle Scholar
  40. 40.
    Kloner RA et al (1981) Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci USA 78:7152–7163PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Huffman C et al (2010) Reversible cardiomyopathies—a review. Transpl Proc 42(9):3673–3678CrossRefGoogle Scholar
  42. 42.
    Iyer VR (2008) Ventricular dysfunction: tachycardia induced cardiomyopathy. Indian Pacing Electrophysiol J 8(Suppl 1):S122–S129Google Scholar
  43. 43.
    Watanabe H et al (2008) Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J 49(1):39–47PubMedCrossRefGoogle Scholar
  44. 44.
    Jeong Y et al (2008) Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 31(4):172–178PubMedCrossRefGoogle Scholar
  45. 45.
    Gentlesk PJ et al (2007) Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 18(1):9–14PubMedCrossRefGoogle Scholar
  46. 46.
    Nerheim P et al (2004) Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110(3):247–252PubMedCrossRefGoogle Scholar
  47. 47.
    Ling L et al (2013) Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy following successful ablation. Circ Arrhythm Electrophysiol 6(4):697–704PubMedCrossRefGoogle Scholar
  48. 48.
    Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: primary prevention. Europace 13:308–328PubMedCrossRefGoogle Scholar
  49. 49.
    Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part II: secondary prevention. EuroPace 13:610–662PubMedCrossRefGoogle Scholar
  50. 50.
    Camm J et al (2012) Focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:2719–2747PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Cardiovascular Medicine, Heart and Vascular InstituteCleveland ClinicClevelandUSA

Personalised recommendations